How much did the AREDS study reduce the odds of advanced AMD progression?
The Age-Related Eye Disease Study found that a specific combination of supplements significantly slowed the progression of macular degeneration. Understanding the exact impact helps seniors make informed choices about their eye health.
✓ Accepted answer
The original AREDS study found that a specific formulation of high-dose antioxidants and zinc reduced the odds of advanced macular degeneration progression by 25 percent over five years.
Key findings from the landmark trial:
- Specific Efficacy: The reduction applied to participants with intermediate age-related macular degeneration or advanced disease in one eye. It did not show a benefit for preventing the initial onset of the condition.
- Standard Formulation: The effective combination included 500 milligrams of vitamin C, 2,000 IU of vitamin E, 10 milligrams of beta-carotene, 80 milligrams of zinc oxide, and 2 milligrams of cupric oxide.
- Updated Recommendations: In 2026, many clinicians now prescribe the AREDS2 formulation, which replaced beta-carotene (a risk factor for lung cancer in smokers) with 10 milligrams of lutein and 2 milligrams of zeaxanthin for improved safety profiles.
Consultation is vital: Before starting these supplements, seniors should speak with an eye care professional to confirm if their specific stage of macular health will actually benefit from this intervention.
Related Questions
- How much blue light do eyes filter by age 60?
- What is Paw Paw Mail and who is it designed for?
- How does long-term amiodarone use affect the optic nerve in elderly patients?
- How much does a $500,000 20-year term life insurance policy cost monthly in 2026?
- What small appliances work best for meal prep in a two-burner kitchen?